A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Trial Profile

A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Azacitidine
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 11 Sep 2017 Planned number of patients changed from 40 to 100.
    • 25 Jun 2017 Results (n=16) presented at the 22nd Congress of the European Haematology Association
    • 16 Feb 2017 Time frame of primary end point has been changed from Up to approximately 18 months to Baseline up to approximately 3.5 years
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top